Element Biosciences

Next-generation sequencing technology provider

San Diego, California, United States

About Element Biosciences

Element Biosciences focuses on next-generation sequencing (NGS) technology, offering the AVITI System, a compact benchtop device that provides high-quality sequencing at a low cost of $1 per million reads. This system is designed for various clients, including academic researchers and pharmaceutical companies, and delivers industry-leading accuracy. Element Biosciences stands out by partnering with other biotech firms, like QIAGEN, to provide complete NGS workflows and by offering the 2023 AVITI for All Grant, which gives free sequencing for diverse applications. The company's goal is to make high-quality sequencing accessible and affordable to accelerate advancements in biotechnology.

San Diego, CaliforniaHeadquarters

2017Year Founded

$659.5MTotal Funding

SERIES_DCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

100% company-paid medical, dental, & vision coverage

Flexible spending & health savings accounts

Premier mental health care

401(k) with immediately vested 4% company match

Company-paid Life and AD&D insurance

Stock option grants

Flexible time off

10 paid annual holidays

8-weeks paid parental leave

Risks

Increased competition from companies like Illumina may impact market share.

Rapid technological advancements require continuous innovation, straining resources.

High cost of AVITI24 may limit adoption among smaller research institutions.

Differentiation

Element Biosciences offers the AVITI System, a low-cost, high-quality sequencing platform.

The company's proprietary technology improves signal-to-noise ratio, enhancing sequencing data quality.

Strategic partnerships with firms like QIAGEN provide comprehensive NGS workflows for clients.

Upsides

AVITI24 platform integrates sequencing and multiomic analysis, revolutionizing cancer research.

Record growth in AVITI System installations indicates strong market demand and acceptance.

Recent executive appointments highlight commitment to leveraging AI for product optimization.

Funding

Total raised$659.51 M

Latest valuation$1.39 B

StageSERIES_D

SERIES D

6/30/2024

$277

$1.39 B

SERIES C

5/31/2021

$276

$1.38 B

SERIES B

5/31/2020

$30

$150.00 M

SERIES A

5/31/2019

$15

$75.00 M